Markets
← Back to Stocks
INCY
INCYTE CORP
Health Care · Biotechnology
$92.87
+0.51%
Vol: 0.0M
Araverus Market Read
Thursday, March 19, 2026
Incyte stock trades modestly lower in pre-market after downgrade, but multiple regulatory catalysts remain on horizon.
Incyte Corporation (INCY) pre-market price at $100.57, down 0.11% after-hours. Jefferies downgraded stock to Hold, yet the company trades at attractive 12.5x 2026 EPS with four potential regulatory catalysts (Jakafi XR, Monjuvi, povorcitinib, Opzelura) within 12-18 months. EPS and revenue expected to grow 9% in 2026.
Price 50d 200d
Previous Market Reads
2 of 2 days↑
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| LLYELI | $916.83 | -0.13% | -11.4% | 21.8x | 0.43 | $821.2B |
| JNJJOHNSON | $237.56 | +0.16% | -1.8% | 18.9x | 0.33 | $572.6B |
| ABBVABBVIE | $206.31 | -0.97% | -11.4% | 12.8x | 0.33 | $364.6B |
| MRKMERCK | $114.17 | -0.29% | -5.4% | 11.7x | 0.26 | $282.3B |
| UNHUNITEDHEALTH | $280.37 | -1.29% | -2.2% | 14.1x | 0.38 | $254.5B |
| AMGNAMGEN | $349.90 | -0.42% | -6.3% | 15.0x | 0.42 | $188.6B |
| ABTABBOTT | $107.19 | -1.12% | -4.5% | 17.2x | 0.74 | $186.3B |
| GILDGILEAD | $141.06 | -0.17% | -8.6% | 14.7x | 0.37 | $175.2B |
| TMOTHERMO | $470.21 | +1.18% | -6.2% | 17.5x | 0.97 | $174.7B |
Fundamentals
Market Cap$18.5B
P/E (TTM)14.5
Forward P/E10.8
Beta0.84
Div Yield—
Prev Close$92.40
RSI (14-Day)
26Oversold
0305070100
52-Week Range
$53.56$92.87$112.29
From High-17.3%
From Low+73.4%
Moving Averages
50d SMA
$100.92-8.0%
200d SMA
$89.56+3.7%
Price between 50d and 200d. Testing 50d support.
Returns
1W
+0.9%
1M
-9.8%
3M
-4.3%
6M
+9.5%
1Y
+54.8%
YTD
-8.4%
Volume
Today44K
20d Avg1.6M
Ratio0.03x